Neurohumoral markers that predict the efficiency of pharmacologic therapy of depressive disorders

1Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.
Get full text

Abstract

We present a comprehensive clinical and biological study of 46 patients with depressive disorder (F32-F33: depressive episode and recurrent depressive disorder) during pharmacotherapy. Neurohumoral factors (cortisol, brain-derived neurotrophic factor, serotonin, DHEA and its sulfated form) were determined in serum by ELISA. The severity of the current depressive episode was evaluated using the 17-point Hamilton Depression Rating Scale (HDRS-17); the pharmacotherapy efficacy was evaluated using the scale of the Clinical Global Impression (CGI Scale). We showed that before prescription of pharmacotherapy peripheral blood neurohumoral markers that characterize the state of stress-realizing and stress-limiting systems of the body may be considered as biological predictors of the effective pharmacotherapy of a current depressive episode and used as additional paraclinical examination methods. At higher concentrations of cortisol and serotonin associated with a decrease in the content of neurosteroid dehydroepiandrosterone, the high efficiency of the pharmacotherapy of depressive episode is predicted.

Cite

CITATION STYLE

APA

Levchuk, L. A., Vyalova, N. M., Simutkin, G. G., Bokhan, N. A., & Ivanova, S. A. (2017). Neurohumoral markers that predict the efficiency of pharmacologic therapy of depressive disorders. Neurochemical Journal, 11(2), 185–187. https://doi.org/10.1134/S1819712417020088

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free